ImmunityBio’s COVID-19 vaccine candidate was selected for Operation Warp Speed, a national program to accelerate COVID-19 vaccine development. Candidate is the first human adenovirus (Ad5) vaccine designed to deliver both Spike (S) and Nucleocapsid (N) DNA for potential long-lasting humoral and
Company Chairman and CEO to Present Clinical Status Report on QUILT Cancer Breakthrough 2020 Trials in Multiple Tumor Types and Data Update on the Company’s N-803 IL-15 Superagonist, which Recently Received Breakthrough Therapy Designation from the FDA CULVER CITY, Calif., January 7, 2020 –
CULVER CITY, Calif. --(BUSINESS WIRE)--Jan. 23, 2017-- NantKwest Inc. (Nasdaq:NK), a pioneering, next-generation, clinical-stage immunotherapy company focused on harnessing the unique power of the immune system using natural killer (NK) cells to treat cancer, infectious diseases, and inflammatory
Dr. Patrick Soon-Shiong keynotes on breakthroughs in immuno-oncology including development of Genomic Proteomic Sequencing test for cancer (GPS Cancer) Phoenix – February 22, 2016 – NantWorks , LLC, NantKwest (Nasdaq: NK), and NantHealth , LLC today announced the scheduled discussion topics
Culver City, California, April 5, 2016 —NantBioScience, Inc., is a biopharmaceutical company focused on the discovery of innovative treatments by developing molecularly targeted drugs, based on the molecular profile of the patient’s tumor, independent of the cancer’s anatomical type.
Immunotherapy Company Will Present Findings at the JP Morgan Healthcare Conference in San Francisco on January 7th Second Round Crossover Funding Brings Celgene’s Investment to $105M in NantCell Valued at $4 Billion Currently Enrolling Patients in Advanced Stage Trials in 15 Indications for
CULVER CITY, Calif. --(BUSINESS WIRE)--Dec. 18, 2015-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using natural killer cells to treat cancer, infectious diseases and inflammatory diseases, today announced that
World’s first combination of tumor-targeted, off-the-shelf PD-L1-targeted Natural Killer cells with IL-15 fusion protein (N-803) to induce immune system activation of both the NK and T-cells demonstrated complete response in second-line metastatic pancreatic cancer, confirmed by PET/CT scan.
Immunotherapy companies led by Dr. Patrick Soon-Shiong are developing potential coronavirus therapeutics and vaccines to address the evolving stages of disease from moderate infection to severe acute respiratory distress syndrome (SARS) Vaccine Vector to Protect Against SARS-CoV-2 Infection:
World’s first combination of off-the-shelf NK with checkpoint inhibitor plus antigen simulation via adenovirus to induce immune system activation Ongoing durable complete responses ranging from 8 to 11 months observed in TNBC patients who failed standard of care Disease control rate of 78% and
